Business Context and Reporting Period
This Form 8-K is filed by NantKwest, Inc. (not Immunitybio, Inc.) for the reporting period ending July 31, 2015. The filing documents corporate governance changes executed in connection with the closing of the Company's initial public offering (IPO).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and structural amendments rather than financial performance data.
Material Changes
- Amended and Restated Certificate of Incorporation: Filed with the Delaware Secretary of State on July 31, 2015, effective upon the closing of the IPO.
- Amended and Restated Bylaws: Adopted by the Board of Directors and stockholders, effective as of July 31, 2015, in connection with the IPO closing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves solely to disclose the adoption of new corporate charter documents.
Investor Verification Checklist
- Verify the specific terms of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) to understand capital structure and shareholder rights.
- Review the Amended and Restated Bylaws (Exhibit 3.2) for governance procedures and board composition rules.
- Confirm the final closing details and share count from the related Form S-1 Registration Statement (File No. 333-205124).